XBiotech's stock plummets
Market Trends

XBiotech’s stock plummets premarket after poor review for cancer treatment

XBiotech Announces Outcome of EMA’s Oral Explanation Meeting BUZ INVESTORS PRESS RELEASE XBiotech’s stock plummets   XBiotech Inc. (NASDAQ:XBIT) announced today that the European Medicines Agency (EMA) rendered a negative “trend” vote after meeting with the Company to discuss the “Day 180 List of Outstanding Issues” related to the Company’s marketing authorization application (MAA) for its […]